Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1986 Sep;41(9):688–691. doi: 10.1136/thx.41.9.688

Short duration combination chemotherapy in the treatment of small cell lung cancer.

A J Dorward, S W Banham, A W Hutcheon, S Ahmedzai, D Cunningham, A Gregor, M Soukop, B H Stack, N S Mackay, S B Kaye
PMCID: PMC460432  PMID: 3024351

Abstract

Ninety five patients (57 with limited disease and 38 with extensive disease) with previously untreated small cell lung cancer were entered into a study of short duration combination chemotherapy with intravenous cyclophosphamide (750 mg/m2) on day 1, adriamycin (40 mg/m2) on day 1, and etoposide VP-16 (100 mg/m2) on days 1, 2, and 3, with the addition on day 10 of methotrexate 50 mg/m2 with folinic acid rescue and vincristine 2 mg. The treatment was repeated on day 22 and only three courses were given. No maintenance chemotherapy was given, though patients with a complete response received radiotherapy (30-40 Gy (3000-4000 rads] to the primary site in most cases. Forty nine patients (86%) with limited disease achieved a response, with 26 (46%) complete remissions. Twenty five patients (66%) with extensive disease had a response, but only eight (21%) had a complete response. Actuarial survival analysis for the whole patient population showed a median survival of 13 months for patients with limited disease and seven months for those with extensive disease. The median survival was 14 months for those patients with limited disease who achieved a complete response, but only 10 months for non-responders. Myelosuppression was the major expression of toxicity. There were three deaths related to treatment and seven patients had febrile episodes during neutropenia that required antibiotics. Mucositis, which was usually mild, occurred in 49% of patients. The primary site was the main site of initial relapse in 56% of the patients who relapsed. Among patients with limited disease who achieved a complete response, relapses at the primary site were less common in those who received radiotherapy (five out of 12) than in those who did not (all eight). The results indicate that this short duration chemotherapy in small cell lung cancer gives response rates and the potential for long term survival similar to those obtained in other series while allowing patients the maximum time free from treatment.

Full text

PDF
688

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Whitacre M., VanEcho D. A., Wesley M., Wiernik P. H. Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer. Cancer Chemother Pharmacol. 1982;7(2-3):187–193. doi: 10.1007/BF00254546. [DOI] [PubMed] [Google Scholar]
  2. Arnold A. M., Williams C. J., Mead G. M., Buchanan R. B., Green J. A., Macbeth F. M., Whitehouse J. M. Combination chemotherapy using high or low dose methotrexate for small cell carcinoma of the lung--a randomised trial. Med Oncol Tumor Pharmacother. 1984;1(1):9–14. doi: 10.1007/BF02935319. [DOI] [PubMed] [Google Scholar]
  3. Byhardt R. W., Cox J. D. Is chest radiotherapy necessary in any or all patients with small cell carcinoma of the lung? Yes. Cancer Treat Rep. 1983 Mar;67(3):209–215. [PubMed] [Google Scholar]
  4. Cohen M. H., Creaven P. J., Fossieck B. E., Jr, Broder L. E., Selawry O. S., Johnston A. V., Williams C. L., Minna J. D. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 1977 May-Jun;61(3):349–354. [PubMed] [Google Scholar]
  5. Cohen M. H. Is thoracic radiation therapy necessary for patients with limited-stage small cell lung cancer? No. Cancer Treat Rep. 1983 Mar;67(3):217–221. [PubMed] [Google Scholar]
  6. Feld R., Evans W. K., DeBoer G., Quirt I. C., Shepherd F. A., Yeoh J. L., Pringle J. F., Payne D. G., Herman J. G., Chamberlain D. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol. 1984 Apr;2(4):294–304. doi: 10.1200/JCO.1984.2.4.294. [DOI] [PubMed] [Google Scholar]
  7. Greco F. A., Einhorn L. H., Richardson R. L., Oldham R. K. Small cell lung cancer: progress and perspectives. Semin Oncol. 1978 Sep;5(3):323–335. [PubMed] [Google Scholar]
  8. Greco F. A., Richardson R. L., Snell J. D., Stroup S. L., Oldham R. K. Small cell lung cancer. Complete remission and improved survival. Am J Med. 1979 Apr;66(4):625–630. doi: 10.1016/0002-9343(79)91173-2. [DOI] [PubMed] [Google Scholar]
  9. Harper P. G., Souhami R. L., Spiro S. G., Geddes D. M., Guimaraes M., Fearon F., Smyth J. F. Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy. Cancer Treat Rep. 1982 Mar;66(3):463–470. [PubMed] [Google Scholar]
  10. Skarin A. T., Canellos G. P., Rosenthal D. S., Case D. C., Jr, MacIntyre J. M., Pinkus G. S., Moloney W. C., Frei E., 3rd Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983 Feb;1(2):91–98. doi: 10.1200/JCO.1983.1.2.91. [DOI] [PubMed] [Google Scholar]
  11. Souhami R. L., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S., Mantell B. S., Fearon F., Bradbury I. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J (Clin Res Ed) 1984 Jun 2;288(6431):1643–1646. doi: 10.1136/bmj.288.6431.1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Thatcher N., Barber P. V., Hunter R. D., Carroll K. B., Jegarajah S., Wilkinson P. M., Crowther D. 11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. Lancet. 1982 May 8;1(8280):1040–1043. doi: 10.1016/s0140-6736(82)92099-2. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES